Who are Colaren in HIV negative's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Switch to DRV/cobicistat + 3TC, FUZEON [enfuvirtide], highly active antiretroviral therapy (HAART), Lopinavir/ritonavir (Kaletra), Reyataz + Norvir + Truvada, TDF/3TC/EFV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/colaren-in-hiv-negative.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Colaren in HIV negative — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Colaren in HIV negative (Colaren in HIV negative) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral. Area: Infectious Diseases.

phase 3 Antiretroviral HIV Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Colaren in HIV negative (Colaren in HIV negative) — University of Guadalajara. Colaren is an investigational drug that targets the HIV virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Colaren in HIV negative TARGET	Colaren in HIV negative	University of Guadalajara	phase 3	Antiretroviral	HIV
Switch to DRV/cobicistat + 3TC	Switch to DRV/cobicistat + 3TC	Hospitales Universitarios Virgen del Rocío	marketed	Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitor)	HIV protease, CYP3A4, HIV reverse transcriptase
FUZEON [enfuvirtide]	FUZEON [enfuvirtide]	Hoffmann-La Roche	marketed	HIV fusion inhibitor	gp41 (HIV envelope glycoprotein)
highly active antiretroviral therapy (HAART)	highly active antiretroviral therapy (HAART)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Antiretroviral	HIV enzymes and processes
Lopinavir/ritonavir (Kaletra)	Lopinavir/ritonavir (Kaletra)	Abbott	marketed	HIV protease inhibitor	HIV protease
Reyataz + Norvir + Truvada	Reyataz + Norvir + Truvada	ViiV Healthcare	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
TDF/3TC/EFV	TDF/3TC/EFV	Peking Union Medical College Hospital	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral class)

A.O. Ospedale Papa Giovanni XXIII · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
Pfizer · 1 drug in this class
University of Guadalajara · 1 drug in this class
ViiV Healthcare · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Colaren in HIV negative — Competitive Intelligence Brief. https://druglandscape.com/ci/colaren-in-hiv-negative. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab